Writing Committee for the REMAP-CAP Investigators IMPORTANCE The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.OBJECTIVE To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTSThe ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021. INTERVENTIONSThe immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916). MAIN OUTCOMES AND MEASURESThe primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, −1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events. RESULTS Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11...

[1] The Suomi National Polar-Orbiting Partnership (NPP) launched on 28 October 2011 hosts the Visible Infrared Imaging Radiometer Suite (VIIRS) sensor. The VIIRS sensor includes a day-night band (DNB) that covers almost 7 orders of magnitude in its dynamic range from full sunlit scenes to lunar-illuminated clouds. The DNB is panchromatic and covers the wavelengths from 500 nm to 900 nm. Since launch, extensive effort has gone into its characterization. We have shown that the DNB is performing extremely well, meeting most of its specifications with some minor exceedances. The DNB characteristics evaluated include the following: sampling and resolution across the swath, geolocation uncertainty, radiometric sensitivity, radiometric uncertainty, and stray light. The only significant deviation from specification involves the stray light specification. On-orbit, the characterization shows that the DNB suffers stray light level on the order of 100% L min or 3 × 10 À9 W•cm À2 •sr À1 . After algorithmic correction, the residual radiometric error was reduced to approximately 4.5 × 10 À10 W•cm À2 •sr À1 .

MMT improved the outcomes of treatment for drug users in ways that might facilitate success of antiretroviral therapy. Integrating MMT to HIV care and treatment services could be beneficial in injection-driven HIV epidemics in resource-scare settings.

Our purpose with this consensus statement is a call to action regarding oral health in sport since there is no evidence of an improving situation. As background, this paper will first summarise the key issues; what we know about oral health in elite sport, the impact of oral health on performance, how oral health might affect performance, why athletes have poor oral health and evidence-based oral health promotion and disease prevention. It will then conclude with recommendations to guide the improvement of oral health in elite athletes. Methods: this consensus statement is informed by a systematic review and subsequent discussion by participants of the symposium, Oral Health and Performance in Sport-Learning from London 2012, 4 April 2014, UCL, London. Since several articles have been written about orofacial trauma previously, the focus of this statement is concerned with oral health. WHAT DO WE KNOW ABOUT ORAL HEALTH IN ELITE SPORT? We conducted a detailed systematic review based on the focused question: 'What is the oral health of athletes and what is the effect of oral health on athletic training and performance?' 4 We searched MEDLINE, EMBASE, EBSCO SPORTDiscus and OpenGrey up to October 2013 with no language restrictions. Duplicate screening, eligibility assessment, data abstraction and methodological quality

No abstract